Key clinical point: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) improves the survival of patients with colorectal cancer (CRC) and peritoneal metastasis.

Major finding: The CRS plus HIPEC vs control group had a longer overall survival (hazard ratio 0.53; P < .00001).

Study details: This was a meta-analysis of 10 studies (3 randomized controlled trials and 7 cohort studies) including 3200 patients with CRC and peritoneal metastasis who were assigned to the CRS plus HIPEC (n = 788) or control (n = 2412) group.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Li J et al. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: A systematic review and meta-analysis. World J Surg Oncol. 2022;20:200 (Jun 14). Doi: 10.1186/s12957-022-02666-3.

Key clinical point: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) improves the survival of patients with colorectal cancer (CRC) and peritoneal metastasis.

Major finding: The CRS plus HIPEC vs control group had a longer overall survival (hazard ratio 0.53; P < .00001).

Study details: This was a meta-analysis of 10 studies (3 randomized controlled trials and 7 cohort studies) including 3200 patients with CRC and peritoneal metastasis who were assigned to the CRS plus HIPEC (n = 788) or control (n = 2412) group.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Li J et al. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: A systematic review and meta-analysis. World J Surg Oncol. 2022;20:200 (Jun 14). Doi: 10.1186/s12957-022-02666-3.

Key clinical point: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) improves the survival of patients with colorectal cancer (CRC) and peritoneal metastasis.

Major finding: The CRS plus HIPEC vs control group had a longer overall survival (hazard ratio 0.53; P < .00001).

Study details: This was a meta-analysis of 10 studies (3 randomized controlled trials and 7 cohort studies) including 3200 patients with CRC and peritoneal metastasis who were assigned to the CRS plus HIPEC (n = 788) or control (n = 2412) group.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Li J et al. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: A systematic review and meta-analysis. World J Surg Oncol. 2022;20:200 (Jun 14). Doi: 10.1186/s12957-022-02666-3.

Key clinical point: Colonoscopy screening prevents both distal and proximal colorectal cancer (CRC) with similar efficacy.

Major finding: After 11 years of follow-up, the colonoscopy screening vs no screening group showed an adjusted CRC risk of 1.62% vs 2.38%, respectively, with the adjusted relative risk (aRR) being 0.68 (95% CI 0.63-0.73). The aRR for distal vs proximal CRC was 0.67 (95% CI 0.62-0.73) vs 0.70 (95% CI 0.63-0.79), respectively.

Study details: This study analyzed the observational data of 307,158 participants from a German claims database who were 55-69 years old, at an average risk for CRC, and did (n = 198,389) or did not (n = 117,399) undergo colonoscopy screening.

Disclosures: This study was supported by intramural funding from the Leibniz Institute for Prevention Research and Epidemiology–BIPS, Germany. The authors declared no conflicts of interest.

Source: Braitmaier M et al. Screening colonoscopy similarly prevented distal and proximal colorectal cancer: a prospective study among 55–69-year-olds J Clin Epidemiol. 2022;149:118-126 (Jun 6). Doi: 10.1016/j.jclinepi.2022.05.024

Key clinical point: Colonoscopy screening prevents both distal and proximal colorectal cancer (CRC) with similar efficacy.

Major finding: After 11 years of follow-up, the colonoscopy screening vs no screening group showed an adjusted CRC risk of 1.62% vs 2.38%, respectively, with the adjusted relative risk (aRR) being 0.68 (95% CI 0.63-0.73). The aRR for distal vs proximal CRC was 0.67 (95% CI 0.62-0.73) vs 0.70 (95% CI 0.63-0.79), respectively.

Study details: This study analyzed the observational data of 307,158 participants from a German claims database who were 55-69 years old, at an average risk for CRC, and did (n = 198,389) or did not (n = 117,399) undergo colonoscopy screening.

Disclosures: This study was supported by intramural funding from the Leibniz Institute for Prevention Research and Epidemiology–BIPS, Germany. The authors declared no conflicts of interest.

Source: Braitmaier M et al. Screening colonoscopy similarly prevented distal and proximal colorectal cancer: a prospective study among 55–69-year-olds J Clin Epidemiol. 2022;149:118-126 (Jun 6). Doi: 10.1016/j.jclinepi.2022.05.024

Key clinical point: Colonoscopy screening prevents both distal and proximal colorectal cancer (CRC) with similar efficacy.

Major finding: After 11 years of follow-up, the colonoscopy screening vs no screening group showed an adjusted CRC risk of 1.62% vs 2.38%, respectively, with the adjusted relative risk (aRR) being 0.68 (95% CI 0.63-0.73). The aRR for distal vs proximal CRC was 0.67 (95% CI 0.62-0.73) vs 0.70 (95% CI 0.63-0.79), respectively.

Study details: This study analyzed the observational data of 307,158 participants from a German claims database who were 55-69 years old, at an average risk for CRC, and did (n = 198,389) or did not (n = 117,399) undergo colonoscopy screening.

Disclosures: This study was supported by intramural funding from the Leibniz Institute for Prevention Research and Epidemiology–BIPS, Germany. The authors declared no conflicts of interest.

Source: Braitmaier M et al. Screening colonoscopy similarly prevented distal and proximal colorectal cancer: a prospective study among 55–69-year-olds J Clin Epidemiol. 2022;149:118-126 (Jun 6). Doi: 10.1016/j.jclinepi.2022.05.024

Key clinical point: Second-line fluorouracil-leucovorin-irinotecan (FOLFIRI)-bevacizumab is associated with a longer overall survival (OS) and progression-free survival (PFS) and better tolerance than FOLFIRI-aflibercept in patients with metastatic colorectal cancer (mCRC) after progression on fluorouracil-leucovorin-oxaliplatin (FOLFOX)-bevacizumab.

Major finding: After a 31.2-month median follow-up, the FOLFIRI-bevacizumab vs FOLFIRI-aflibercept group had a significantly longer median OS (13.0 vs 10.4 months; P < .0001) and PFS (6.01 vs 5.09 months; P < .0001) and a lower grade 3-4 toxicity rate (P < .0001), with bevacizumab being associated with better OS (adjusted hazard ratio [aHR] 0.71; P  =  .0003) and PFS (aHR 0.70; P  =  .0001) even after confounder adjustment.

Study details: Findings are from a retrospective, real-world cohort study, BEFLICO, that included 681 patients with mCRC who received FOLFIRI-aflibercept (n = 326) or FOLFIRI-bevacizumab (n = 355) in the second-line setting.

Disclosures: This study was supported by the Association des Gastro-entérologues Oncologues (AGEO). Some authors reported receiving speaker/advisor honoraria, consulting/personal fees, and/or research/travel funding from various sources.

Source: Torregrosa C et al. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study. Int J Cancer. 2022 (Jun 15). Doi:  10.1002/ijc.34166

Key clinical point: Second-line fluorouracil-leucovorin-irinotecan (FOLFIRI)-bevacizumab is associated with a longer overall survival (OS) and progression-free survival (PFS) and better tolerance than FOLFIRI-aflibercept in patients with metastatic colorectal cancer (mCRC) after progression on fluorouracil-leucovorin-oxaliplatin (FOLFOX)-bevacizumab.

Major finding: After a 31.2-month median follow-up, the FOLFIRI-bevacizumab vs FOLFIRI-aflibercept group had a significantly longer median OS (13.0 vs 10.4 months; P < .0001) and PFS (6.01 vs 5.09 months; P < .0001) and a lower grade 3-4 toxicity rate (P < .0001), with bevacizumab being associated with better OS (adjusted hazard ratio [aHR] 0.71; P  =  .0003) and PFS (aHR 0.70; P  =  .0001) even after confounder adjustment.

Study details: Findings are from a retrospective, real-world cohort study, BEFLICO, that included 681 patients with mCRC who received FOLFIRI-aflibercept (n = 326) or FOLFIRI-bevacizumab (n = 355) in the second-line setting.

Disclosures: This study was supported by the Association des Gastro-entérologues Oncologues (AGEO). Some authors reported receiving speaker/advisor honoraria, consulting/personal fees, and/or research/travel funding from various sources.

Source: Torregrosa C et al. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study. Int J Cancer. 2022 (Jun 15). Doi:  10.1002/ijc.34166

Key clinical point: Second-line fluorouracil-leucovorin-irinotecan (FOLFIRI)-bevacizumab is associated with a longer overall survival (OS) and progression-free survival (PFS) and better tolerance than FOLFIRI-aflibercept in patients with metastatic colorectal cancer (mCRC) after progression on fluorouracil-leucovorin-oxaliplatin (FOLFOX)-bevacizumab.

Major finding: After a 31.2-month median follow-up, the FOLFIRI-bevacizumab vs FOLFIRI-aflibercept group had a significantly longer median OS (13.0 vs 10.4 months; P < .0001) and PFS (6.01 vs 5.09 months; P < .0001) and a lower grade 3-4 toxicity rate (P < .0001), with bevacizumab being associated with better OS (adjusted hazard ratio [aHR] 0.71; P  =  .0003) and PFS (aHR 0.70; P  =  .0001) even after confounder adjustment.

Study details: Findings are from a retrospective, real-world cohort study, BEFLICO, that included 681 patients with mCRC who received FOLFIRI-aflibercept (n = 326) or FOLFIRI-bevacizumab (n = 355) in the second-line setting.

Disclosures: This study was supported by the Association des Gastro-entérologues Oncologues (AGEO). Some authors reported receiving speaker/advisor honoraria, consulting/personal fees, and/or research/travel funding from various sources.

Source: Torregrosa C et al. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study. Int J Cancer. 2022 (Jun 15). Doi:  10.1002/ijc.34166

Key clinical point: In combination with 6 months of fluoropyrimidine therapy, 3 vs 6 months of oxaliplatin treatment (3- vs 6-month arm, respectively) is noninferior in patients with high-risk stage II or III colorectal cancer (CRC).

Major finding: The 3- vs 6-month arm showed significantly lower any-grade neuropathy rates (58.3% vs 69.5%; P < .0001) and comparable 3-year disease-free survival rates (84.7% vs 83.7%) with a hazard ratio of 0.953 (P_{noninferiority}  =  .0065), which was within the noninferiority margin of 1.25.

Study details: Findings are from a multicenter, phase 3 trial that included 1788 patients with high-risk stage II or III CRC who were randomly assigned to receive 3 (n = 893) or 6 (n = 895) months of oxaliplatin with 6 months of fluoropyrimidine therapy.

Disclosures: This study was sponsored by the Colorectal Cancer Committee of the Korean Cancer Study Group and Sanofi. Some authors declared serving as consultants or advisors for or receiving research funding from various sources, including Sanofi.

Source: Kim ST et al. Oxaliplatin (3 months v 6 months) with 6 months of fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer: KCSG CO09-07. J Clin Oncol. 2022 (Jun 30). Doi:  10.1200/JCO.21.02962

Key clinical point: In combination with 6 months of fluoropyrimidine therapy, 3 vs 6 months of oxaliplatin treatment (3- vs 6-month arm, respectively) is noninferior in patients with high-risk stage II or III colorectal cancer (CRC).

Major finding: The 3- vs 6-month arm showed significantly lower any-grade neuropathy rates (58.3% vs 69.5%; P < .0001) and comparable 3-year disease-free survival rates (84.7% vs 83.7%) with a hazard ratio of 0.953 (P_{noninferiority}  =  .0065), which was within the noninferiority margin of 1.25.

Study details: Findings are from a multicenter, phase 3 trial that included 1788 patients with high-risk stage II or III CRC who were randomly assigned to receive 3 (n = 893) or 6 (n = 895) months of oxaliplatin with 6 months of fluoropyrimidine therapy.

Disclosures: This study was sponsored by the Colorectal Cancer Committee of the Korean Cancer Study Group and Sanofi. Some authors declared serving as consultants or advisors for or receiving research funding from various sources, including Sanofi.

Source: Kim ST et al. Oxaliplatin (3 months v 6 months) with 6 months of fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer: KCSG CO09-07. J Clin Oncol. 2022 (Jun 30). Doi:  10.1200/JCO.21.02962

Key clinical point: In combination with 6 months of fluoropyrimidine therapy, 3 vs 6 months of oxaliplatin treatment (3- vs 6-month arm, respectively) is noninferior in patients with high-risk stage II or III colorectal cancer (CRC).

Major finding: The 3- vs 6-month arm showed significantly lower any-grade neuropathy rates (58.3% vs 69.5%; P < .0001) and comparable 3-year disease-free survival rates (84.7% vs 83.7%) with a hazard ratio of 0.953 (P_{noninferiority}  =  .0065), which was within the noninferiority margin of 1.25.

Study details: Findings are from a multicenter, phase 3 trial that included 1788 patients with high-risk stage II or III CRC who were randomly assigned to receive 3 (n = 893) or 6 (n = 895) months of oxaliplatin with 6 months of fluoropyrimidine therapy.

Disclosures: This study was sponsored by the Colorectal Cancer Committee of the Korean Cancer Study Group and Sanofi. Some authors declared serving as consultants or advisors for or receiving research funding from various sources, including Sanofi.

Source: Kim ST et al. Oxaliplatin (3 months v 6 months) with 6 months of fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer: KCSG CO09-07. J Clin Oncol. 2022 (Jun 30). Doi:  10.1200/JCO.21.02962

Key clinical point: A Western-style diet (rich in red and processed meat) is more strongly associated with colorectal cancer (CRC) incidence for tumors containing higher amounts of polyketide synthase (pks)+ Escherichia coli.

Major finding: The association between the Western diet score and CRC incidence was stronger for tumors with higher pks+ E. coli levels (P_{heterogeneity}  =  .014). Individuals in the highest vs lowest tertile of diet score with pks+ E. coli-high, -low, and -negative tumors had adjusted hazard ratios of 3.45 (95% CI 1.53-7.78; P_trend  =  .001), 1.22 (95% CI 0.57-2.63), and 1.10 (95% CI 0.85-1.42), respectively.

Study details: This study analyzed the dietary information of 134,775 individuals enrolled in 2 U.S.-wide longitudinal prospective cohort studies using semiquantitative food frequency questionnaires.

Disclosures: This study was sponsored by the US National Institutes of Health, among others. Some authors declared previously serving as advisors or consultants for or receiving research grants from various sources.

Source: Arima K et al. Western-style diet, pks island-carrying Escherichia coli, and colorectal cancer: Analyses from two large prospective cohort studies. Gastroenterology. 2022 (Jun 24). Doi:  10.1053/j.gastro.2022.06.054

Key clinical point: A Western-style diet (rich in red and processed meat) is more strongly associated with colorectal cancer (CRC) incidence for tumors containing higher amounts of polyketide synthase (pks)+ Escherichia coli.

Major finding: The association between the Western diet score and CRC incidence was stronger for tumors with higher pks+ E. coli levels (P_{heterogeneity}  =  .014). Individuals in the highest vs lowest tertile of diet score with pks+ E. coli-high, -low, and -negative tumors had adjusted hazard ratios of 3.45 (95% CI 1.53-7.78; P_trend  =  .001), 1.22 (95% CI 0.57-2.63), and 1.10 (95% CI 0.85-1.42), respectively.

Study details: This study analyzed the dietary information of 134,775 individuals enrolled in 2 U.S.-wide longitudinal prospective cohort studies using semiquantitative food frequency questionnaires.

Disclosures: This study was sponsored by the US National Institutes of Health, among others. Some authors declared previously serving as advisors or consultants for or receiving research grants from various sources.

Source: Arima K et al. Western-style diet, pks island-carrying Escherichia coli, and colorectal cancer: Analyses from two large prospective cohort studies. Gastroenterology. 2022 (Jun 24). Doi:  10.1053/j.gastro.2022.06.054

Key clinical point: A Western-style diet (rich in red and processed meat) is more strongly associated with colorectal cancer (CRC) incidence for tumors containing higher amounts of polyketide synthase (pks)+ Escherichia coli.

Major finding: The association between the Western diet score and CRC incidence was stronger for tumors with higher pks+ E. coli levels (P_{heterogeneity}  =  .014). Individuals in the highest vs lowest tertile of diet score with pks+ E. coli-high, -low, and -negative tumors had adjusted hazard ratios of 3.45 (95% CI 1.53-7.78; P_trend  =  .001), 1.22 (95% CI 0.57-2.63), and 1.10 (95% CI 0.85-1.42), respectively.

Study details: This study analyzed the dietary information of 134,775 individuals enrolled in 2 U.S.-wide longitudinal prospective cohort studies using semiquantitative food frequency questionnaires.

Disclosures: This study was sponsored by the US National Institutes of Health, among others. Some authors declared previously serving as advisors or consultants for or receiving research grants from various sources.

Source: Arima K et al. Western-style diet, pks island-carrying Escherichia coli, and colorectal cancer: Analyses from two large prospective cohort studies. Gastroenterology. 2022 (Jun 24). Doi:  10.1053/j.gastro.2022.06.054

Key clinical point: Use of circulating tumor DNA (ctDNA)-guided approach for treating stage II colon cancer decreases the use of adjuvant chemotherapy without altering the risk for recurrence.

Major finding: After a median follow-up of 37 months, patients receiving ctDNA-guided vs standard management had a lower adjuvant chemotherapy rate (15% vs 28%; relative risk 1.82; 95% CI 1.25-2.65) and a similar 2-year recurrence-free survival rate (93.5% vs 92.4%; absolute difference, 1.1 percentage points; 95% CI −4.1 to 6.2 [noninferiority margin −8.5 percentage points]).

Study details: The data come from a multicenter phase 2 trial, DYNAMIC, involving 455 patients with resected stage II colon cancer who were assigned to ctDNA-guided (n = 302) or standard (n = 153) management.

Disclosures: This study was sponsored by the Australian National Health and Medical Research Council and other sources. The authors declared no conflicts of interest.

Source: Tie J et al for the DYNAMIC Investigators. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386:2261-2272 (Jun 16). Doi: 10.1056/NEJMoa2200075

Key clinical point: Use of circulating tumor DNA (ctDNA)-guided approach for treating stage II colon cancer decreases the use of adjuvant chemotherapy without altering the risk for recurrence.

Major finding: After a median follow-up of 37 months, patients receiving ctDNA-guided vs standard management had a lower adjuvant chemotherapy rate (15% vs 28%; relative risk 1.82; 95% CI 1.25-2.65) and a similar 2-year recurrence-free survival rate (93.5% vs 92.4%; absolute difference, 1.1 percentage points; 95% CI −4.1 to 6.2 [noninferiority margin −8.5 percentage points]).

Study details: The data come from a multicenter phase 2 trial, DYNAMIC, involving 455 patients with resected stage II colon cancer who were assigned to ctDNA-guided (n = 302) or standard (n = 153) management.

Disclosures: This study was sponsored by the Australian National Health and Medical Research Council and other sources. The authors declared no conflicts of interest.

Source: Tie J et al for the DYNAMIC Investigators. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386:2261-2272 (Jun 16). Doi: 10.1056/NEJMoa2200075

Key clinical point: Use of circulating tumor DNA (ctDNA)-guided approach for treating stage II colon cancer decreases the use of adjuvant chemotherapy without altering the risk for recurrence.

Major finding: After a median follow-up of 37 months, patients receiving ctDNA-guided vs standard management had a lower adjuvant chemotherapy rate (15% vs 28%; relative risk 1.82; 95% CI 1.25-2.65) and a similar 2-year recurrence-free survival rate (93.5% vs 92.4%; absolute difference, 1.1 percentage points; 95% CI −4.1 to 6.2 [noninferiority margin −8.5 percentage points]).

Study details: The data come from a multicenter phase 2 trial, DYNAMIC, involving 455 patients with resected stage II colon cancer who were assigned to ctDNA-guided (n = 302) or standard (n = 153) management.

Disclosures: This study was sponsored by the Australian National Health and Medical Research Council and other sources. The authors declared no conflicts of interest.

Source: Tie J et al for the DYNAMIC Investigators. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386:2261-2272 (Jun 16). Doi: 10.1056/NEJMoa2200075

Key clinical point: Abatacept significantly improved disease activity compared with tumor necrosis factor inhibitors (TNFi) in a real-world population of patients with established anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA).

Major finding: At 1-year, the mean change in clinical disease activity index (CDAI) score was significantly higher with abatacept vs TNFi (−16.78 vs −13.61; P  =  .020), with a higher proportion of patients receiving abatacept vs TNFi achieving CDAI remission or low disease activity (68% vs 52.6%; P  =  .013).

Study details: The data come from an observational cohort study that propensity-score matched 291 patients with ACPA-positive RA who initiated abatacept (n = 97) or TNFi (n = 194).

Disclosures: This study was sponsored by Bristol-Myers Squibb. The authors declared no conflicts of interest.

Source: Kim MJ, Lee S-K, et al. Efficacy of abatacept versus tumor necrosis factor inhibitors in anti-citrullinated protein antibody-positive patients with rheumatoid arthritis: Results from a Korean nationwide biologics registry. Rheumatol Ther. 2022 (Jun 18). Doi: 10.1007/s40744-022-00467-4

Key clinical point: Abatacept significantly improved disease activity compared with tumor necrosis factor inhibitors (TNFi) in a real-world population of patients with established anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA).

Major finding: At 1-year, the mean change in clinical disease activity index (CDAI) score was significantly higher with abatacept vs TNFi (−16.78 vs −13.61; P  =  .020), with a higher proportion of patients receiving abatacept vs TNFi achieving CDAI remission or low disease activity (68% vs 52.6%; P  =  .013).

Study details: The data come from an observational cohort study that propensity-score matched 291 patients with ACPA-positive RA who initiated abatacept (n = 97) or TNFi (n = 194).

Disclosures: This study was sponsored by Bristol-Myers Squibb. The authors declared no conflicts of interest.

Source: Kim MJ, Lee S-K, et al. Efficacy of abatacept versus tumor necrosis factor inhibitors in anti-citrullinated protein antibody-positive patients with rheumatoid arthritis: Results from a Korean nationwide biologics registry. Rheumatol Ther. 2022 (Jun 18). Doi: 10.1007/s40744-022-00467-4

Key clinical point: Abatacept significantly improved disease activity compared with tumor necrosis factor inhibitors (TNFi) in a real-world population of patients with established anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA).

Major finding: At 1-year, the mean change in clinical disease activity index (CDAI) score was significantly higher with abatacept vs TNFi (−16.78 vs −13.61; P  =  .020), with a higher proportion of patients receiving abatacept vs TNFi achieving CDAI remission or low disease activity (68% vs 52.6%; P  =  .013).

Study details: The data come from an observational cohort study that propensity-score matched 291 patients with ACPA-positive RA who initiated abatacept (n = 97) or TNFi (n = 194).

Disclosures: This study was sponsored by Bristol-Myers Squibb. The authors declared no conflicts of interest.

Source: Kim MJ, Lee S-K, et al. Efficacy of abatacept versus tumor necrosis factor inhibitors in anti-citrullinated protein antibody-positive patients with rheumatoid arthritis: Results from a Korean nationwide biologics registry. Rheumatol Ther. 2022 (Jun 18). Doi: 10.1007/s40744-022-00467-4

Key clinical point: Attempting discontinuation of biologic disease-modifying antirheumatic drugs (bDMARD) or tofacitinib may be a feasible option in patients with rheumatoid arthritis (RA) and can be pursued after achieving stable control of disease activity.

Major finding: During a mean follow-up period of 2.1 years after discontinuing bDMARD or tofacitinib, disease flare occurred in 76.3% of patients (incidence rate 0.36 per person-year), with the median time to flare being 1.6 years (95% CI 0.9-2.6 years) and 89% of patients regaining remission or low disease activity within 1 month of restarting the previous treatment.

Study details: This was a prospective, observational study including 97 patients with RA in sustained remission or low disease activity for ≥ 48 weeks after a stable treatment with bDMARD or tofacitinib who desired drug discontinuation but received a stable methotrexate dose during follow-up.

Disclosures: This study was supported by the National Hospital Organization, Japan. S Mori reported receiving lecture fees from various sources.

Source: Mori S et al. Long-term outcomes after discontinuing biological drugs and tofacitinib in patients with rheumatoid arthritis: A prospective cohort study. PLoS One. 2022;17(6):e0270391 (Jun 23). Doi: 10.1371/journal.pone.0270391

Key clinical point: Attempting discontinuation of biologic disease-modifying antirheumatic drugs (bDMARD) or tofacitinib may be a feasible option in patients with rheumatoid arthritis (RA) and can be pursued after achieving stable control of disease activity.

Major finding: During a mean follow-up period of 2.1 years after discontinuing bDMARD or tofacitinib, disease flare occurred in 76.3% of patients (incidence rate 0.36 per person-year), with the median time to flare being 1.6 years (95% CI 0.9-2.6 years) and 89% of patients regaining remission or low disease activity within 1 month of restarting the previous treatment.

Study details: This was a prospective, observational study including 97 patients with RA in sustained remission or low disease activity for ≥ 48 weeks after a stable treatment with bDMARD or tofacitinib who desired drug discontinuation but received a stable methotrexate dose during follow-up.

Disclosures: This study was supported by the National Hospital Organization, Japan. S Mori reported receiving lecture fees from various sources.

Source: Mori S et al. Long-term outcomes after discontinuing biological drugs and tofacitinib in patients with rheumatoid arthritis: A prospective cohort study. PLoS One. 2022;17(6):e0270391 (Jun 23). Doi: 10.1371/journal.pone.0270391

Key clinical point: Attempting discontinuation of biologic disease-modifying antirheumatic drugs (bDMARD) or tofacitinib may be a feasible option in patients with rheumatoid arthritis (RA) and can be pursued after achieving stable control of disease activity.

Major finding: During a mean follow-up period of 2.1 years after discontinuing bDMARD or tofacitinib, disease flare occurred in 76.3% of patients (incidence rate 0.36 per person-year), with the median time to flare being 1.6 years (95% CI 0.9-2.6 years) and 89% of patients regaining remission or low disease activity within 1 month of restarting the previous treatment.

Study details: This was a prospective, observational study including 97 patients with RA in sustained remission or low disease activity for ≥ 48 weeks after a stable treatment with bDMARD or tofacitinib who desired drug discontinuation but received a stable methotrexate dose during follow-up.

Disclosures: This study was supported by the National Hospital Organization, Japan. S Mori reported receiving lecture fees from various sources.

Source: Mori S et al. Long-term outcomes after discontinuing biological drugs and tofacitinib in patients with rheumatoid arthritis: A prospective cohort study. PLoS One. 2022;17(6):e0270391 (Jun 23). Doi: 10.1371/journal.pone.0270391

Key clinical point: Abatacept stabilized pulmonary function and joint inflammation in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and had a favorable safety profile.

Major finding: Abatacept improved or stabilized lung disease in 72% of patients, with the median survival until progression or death being 72 months (95% CI 34-110 months). No significant decrease in the forced vital capacity or diffusing capacity of the lung for carbon monoxide and a significant improvement in 28-joint Disease Activity Score (P  =  .024) were observed. Overall, 10.5% of patients reported severe adverse events.

Study details: This was a prospective, observational cohort study including 57 patients with RA-ILD who received abatacept as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs, immunosuppressants, antifibrotic agents, or corticosteroids.

Disclosures: This study received grants from Fundación Andaluza de Reumatología and Instituto de Investigación Biomédica de Málaga, Spain. The authors declared no conflicts of interest.

Source: Mena-Vázquez N et al. Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis–associated interstitial lung disease. Biomedicines. 2022;10(7):1480 (Jun 22). Doi: 10.3390/biomedicines10071480

Key clinical point: Abatacept stabilized pulmonary function and joint inflammation in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and had a favorable safety profile.

Major finding: Abatacept improved or stabilized lung disease in 72% of patients, with the median survival until progression or death being 72 months (95% CI 34-110 months). No significant decrease in the forced vital capacity or diffusing capacity of the lung for carbon monoxide and a significant improvement in 28-joint Disease Activity Score (P  =  .024) were observed. Overall, 10.5% of patients reported severe adverse events.

Study details: This was a prospective, observational cohort study including 57 patients with RA-ILD who received abatacept as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs, immunosuppressants, antifibrotic agents, or corticosteroids.

Disclosures: This study received grants from Fundación Andaluza de Reumatología and Instituto de Investigación Biomédica de Málaga, Spain. The authors declared no conflicts of interest.

Source: Mena-Vázquez N et al. Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis–associated interstitial lung disease. Biomedicines. 2022;10(7):1480 (Jun 22). Doi: 10.3390/biomedicines10071480

Key clinical point: Abatacept stabilized pulmonary function and joint inflammation in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and had a favorable safety profile.

Major finding: Abatacept improved or stabilized lung disease in 72% of patients, with the median survival until progression or death being 72 months (95% CI 34-110 months). No significant decrease in the forced vital capacity or diffusing capacity of the lung for carbon monoxide and a significant improvement in 28-joint Disease Activity Score (P  =  .024) were observed. Overall, 10.5% of patients reported severe adverse events.

Study details: This was a prospective, observational cohort study including 57 patients with RA-ILD who received abatacept as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs, immunosuppressants, antifibrotic agents, or corticosteroids.

Disclosures: This study received grants from Fundación Andaluza de Reumatología and Instituto de Investigación Biomédica de Málaga, Spain. The authors declared no conflicts of interest.

Source: Mena-Vázquez N et al. Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis–associated interstitial lung disease. Biomedicines. 2022;10(7):1480 (Jun 22). Doi: 10.3390/biomedicines10071480

Key clinical point: Hospitalized patients with rheumatoid arthritis (RA) with vs without prior bariatric surgery were less likely to have in-hospital deaths, major morbidities, unfavorable discharges, and prolonged length of stay (LOS).

Major finding: Patients with vs without prior bariatric surgery were at a reduced risk for any morbidity (adjusted odds ratio [aOR] 0.45; 95% CI 0.42-0.48), in-hospital mortality (aOR 0.41; 95% CI 0.27-0.61), unfavorable discharge (aOR 0.48; 95% CI 0.44-0.53), and prolonged LOS (aOR 0.43; 95% CI 0.39-0.46).

Study details: This population-based, retrospective study included 33,075 hospitalized patients with morbid obesity and RA, of which 6615 patients with prior bariatric surgery were propensity-score matched with 26,460 patients without prior bariatric surgery.

Disclosures: This study did not declare any source of funding. The authors declared no conflicts of interest.

Source: Lin I-C and Liu H. Impact of bariatric surgery on outcomes of patients with rheumatoid arthritis: A propensity score–matched analysis of US nationwide inpatient sample, 2005–2018. Obes Surg. 2022 (Jun 29). Doi: 10.1007/s11695-022-06177-8

Key clinical point: Hospitalized patients with rheumatoid arthritis (RA) with vs without prior bariatric surgery were less likely to have in-hospital deaths, major morbidities, unfavorable discharges, and prolonged length of stay (LOS).

Major finding: Patients with vs without prior bariatric surgery were at a reduced risk for any morbidity (adjusted odds ratio [aOR] 0.45; 95% CI 0.42-0.48), in-hospital mortality (aOR 0.41; 95% CI 0.27-0.61), unfavorable discharge (aOR 0.48; 95% CI 0.44-0.53), and prolonged LOS (aOR 0.43; 95% CI 0.39-0.46).

Study details: This population-based, retrospective study included 33,075 hospitalized patients with morbid obesity and RA, of which 6615 patients with prior bariatric surgery were propensity-score matched with 26,460 patients without prior bariatric surgery.

Disclosures: This study did not declare any source of funding. The authors declared no conflicts of interest.

Source: Lin I-C and Liu H. Impact of bariatric surgery on outcomes of patients with rheumatoid arthritis: A propensity score–matched analysis of US nationwide inpatient sample, 2005–2018. Obes Surg. 2022 (Jun 29). Doi: 10.1007/s11695-022-06177-8

Key clinical point: Hospitalized patients with rheumatoid arthritis (RA) with vs without prior bariatric surgery were less likely to have in-hospital deaths, major morbidities, unfavorable discharges, and prolonged length of stay (LOS).

Major finding: Patients with vs without prior bariatric surgery were at a reduced risk for any morbidity (adjusted odds ratio [aOR] 0.45; 95% CI 0.42-0.48), in-hospital mortality (aOR 0.41; 95% CI 0.27-0.61), unfavorable discharge (aOR 0.48; 95% CI 0.44-0.53), and prolonged LOS (aOR 0.43; 95% CI 0.39-0.46).

Study details: This population-based, retrospective study included 33,075 hospitalized patients with morbid obesity and RA, of which 6615 patients with prior bariatric surgery were propensity-score matched with 26,460 patients without prior bariatric surgery.

Disclosures: This study did not declare any source of funding. The authors declared no conflicts of interest.

Source: Lin I-C and Liu H. Impact of bariatric surgery on outcomes of patients with rheumatoid arthritis: A propensity score–matched analysis of US nationwide inpatient sample, 2005–2018. Obes Surg. 2022 (Jun 29). Doi: 10.1007/s11695-022-06177-8